Location: University of Konstanz (Germany) Date of
establishment: 2005
Duration of
contract: 10 years financed by the DZF End of
furtherance: 2015 (will be further supported by the state of Baden-Württemberg) Chairholder: Prof. dr. Marcel Leist
The Dorenkamp-Zbinden Chair
at the University of Konstanz in Germany was the first of several endowed
professorships founded by the Doerenkamp-Zbinden Foundation. It was established
in 2003 under the name “The Doerenkamp-Zbinden Professorship of Consumer Protection
and Health” in order to promote research and teaching in the area of the 3R
(Refinement, Replacement, Reduction of animal experiments). Under the influence
of the modern scientific currents and developments, additionally influenced and
determined by new toxicological approaches as formulated by the National
Research Council of the USA in 2007 in its vision and roadmap document on a
“Toxicology for the 21st century”, the chair changed its name in “The Doerenkamp-Zbinden
Chair of in-vitro Toxicology and Biomedicine”. The aim of the chair has stayed
the same working strongly toward the 3Rs approach in teaching and research. The
new activities and research of the chair have focused more on pharmacological and toxicological research in the areas of neurodevelopment and neurodegeneration.
Besides experimental research, the chair conceptualizes new toxicological approaches within the "transatlantic think tank for toxicology (t4)", and is strongly involved in promoting research and development in the field of alternative methods to animal experimentation, within a joint venture of CAAT-Europe (Center for Alternatives to Animal Testing) in Konstanz and CAAT at the Bloomberg School of Public Health at Johns-Hopkins University in Baltimore.
For more information about
the team, projects and activities of the Chair at the University of Konstanz
please click the following link:
→ The
Doerenkamp-Zbinden Chair of in-vitro Toxicology and Biomedicine
Highlighted projects:
- Replacement of animal experiments in
Parkinson’s research
- In vitro cell differentiation assays to replace rodent and companion
animal use in tests of neurotoxicity and embryotoxicity
- Establishment and validation of an
improved in vitro model of the blood brain
- Development of in vitro embryonic stem
cell-based cell assays to screen for toxicity of emerging nanomaterials
|